Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (JAZZ) Stock Overview
Explore Jazz Pharmaceuticals plc’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
10.5B
P/E Ratio
-28.28
EPS (TTM)
$-6.16
ROE
-0.09%
JAZZ Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Jazz Pharmaceuticals plc (JAZZ) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 62.03, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $137.67.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -28.28 and a market capitalization of 10.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.